Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totaling 1,083,465 shares, a drop of 45.5% from the April 15th total of 1,989,468 shares. Based on an average trading volume of 2,651,998 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.4% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Liminatus Pharma Stock Performance

NASDAQ LIMN traded down $0.00 during mid-day trading on Friday, reaching $0.18. 754,434 shares of the stock were exchanged, compared to its average volume of 1,005,395. Liminatus Pharma has a 1-year low of $0.16 and a 1-year high of $33.66. The business’s fifty day simple moving average is $0.20 and its 200 day simple moving average is $0.61. The stock has a market capitalization of $8.08 million and a PE ratio of -1.20.

Liminatus Pharma (NASDAQ:LIMN) last announced its earnings results on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.